- Tryp Therapeutics recently launched a new website with updated resources to be featured on the site
- Over the next few weeks, the company will share key resources that will be the standout features of the new website
- Tryp believes that the new features represent expanded knowledge of the company’s strategy and will present more opportunities to existing investors and bring in more individuals who share in its course
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has, since its inception, led the next wave of psychedelic drug development beyond mental health. Its focus on areas of high unmet medical needs and bring relief to millions of people worldwide who are dealing with conditions such as fibromyalgia, CRPS, and Phantom Limb Pain but lack proper treatment for their conditions.
In a move that demonstrates its commitment to taking its operations further and having even a broader market reach, Tryp recently updated its website in an act to better represent the company’s current stage of development. Additionally, it plans to distribute critical resources that will be featured on its updated site, and which will act as a tool for the investment community.
Some of these resources will include an Investor Pack that will cover Tryp’s pitch deck, a factsheet, and a Frequently Asked Questions (“FAQ”) section. There will also be a dedicated FAQ for patients, coupled with a series of short QA videos from the management team.
The updated website will also feature market opportunity info, along with QA with two key individuals. One will be Dr. Jennifer Miller, the Principal Investigator for a clinical trial to treat symptoms associated with eating disorders (https://ibn.fm/DQChR), and the other will be Kevin Boehnke, the Principal Investigator for Phase 2a clinical trial on the treatment of fibromyalgia (https://ibn.fm/Z8RON).
Tryp believes that making these critical resources assessable on the website will present more diligence opportunities to patients suffering from their targeted indications and existing investors. It also believes that by doing so, it will bring in more individuals who will share in its course, allowing them to be part of a movement dedicated to improving millions of lives around the world (https://ibn.fm/rVAHw).
Over the next few weeks, the company provide updates regarding essential resources that will be the standout features of the new website. This is happening in tandem with ushering a new era for psilocybin, with Tryp’s commitment to revolutionizing what psilocybin-based treatments can do with leading-edge therapies for chronic pain and other indications.
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
